At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Apr 8, 2026 at 20:00 ET
HUTCHMED announced upcoming presentations of preclinical data for HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC), and updated clinical results for surufatinib combinations at the AACR 2026 meeting. The data highlight the novel mechanism and anti-tumor activity of HMPL-A580 in EGFR-expressing tumors and provide updates on ongoing trials in gastrointestinal and pancreatic cancers.
- Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR ATTC, will be presented at AACR 2026, showing potent and selective inhibition of tumor cell proliferation in EGFR-expressing models.
- HMPL-A580 demonstrated dose-dependent anti-tumor activity in xenograft models and favorable pharmacokinetics in monkeys, supporting its potential as a targeted therapy with improved safety over existing PAM inhibitors.
- Updated Phase Ib/II data for surufatinib plus sintilimab and capecitabine in metastatic small bowel and appendiceal carcinoma will be presented.
- Exploratory Phase II data on surufatinib combined with gemcitabine/nab-paclitaxel in pancreatic cancer following induction therapy will also be shared.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access